Myomo (MYO) Amortization of Deferred Charges (2020 - 2021)
Myomo's (MYO) quarterly Amortization of Deferred Charges came in at -$99947.0 in Q2 2021, down 349.87% on a YoY basis from $40000.0 in Q2 2020, and down 159.99% quarter-over-quarter from $166600.0 in Q1 2021.
Powered by 
Analysis
Myomo (MYO) Amortization of Deferred Charges (2020 - 2021) Analysis & Trends
Myomo (MYO) has reported Amortization of Deferred Charges for 2 consecutive years, with -$99947.0 the latest figure, recorded in Q2 2021.
- For the quarter ending Q2 2021, Amortization of Deferred Charges fell 349.87% year-over-year to -$99947.0; the trailing twelve-month figure through Jun 2021 stood at $78753.0 (down 26.49% YoY), and the FY2020 full-year result was $161869.0, up 177.67% from the prior year.
- Amortization of Deferred Charges eased to -$99947.0 in Q2 2021 per MYO's latest filing, from $166600.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $166600.0 in Q1 2021 and bottomed at -$99947.0 in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn |
| 9 | Steris | 21.90 Bn | 21.43 Bn | 684.20 Mn |
| 10 | Myomo | 54.96 Mn | 35.99 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | -99,947.00 |
| Mar 31, 2021 | 166,600.00 |
| Sep 30, 2020 | 12,100.00 |
| Jun 30, 2020 | 40,000.00 |
| Mar 31, 2020 | 67,132.00 |